Catalyst Pharmaceuticals Inc. closed 13.60% below its 52-week high of $26.16, which the company reached on March 24th.

Catalyst Pharmaceuticals Inc. closed 15.82% short of its 52-week high of $26.16, which the company achieved on March 24th.

China's CATL on Monday launched a new brand for its sodium-ion batteries, Naxtra, which it said would go into mass production ...

BofA raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $34 from $33 and keeps a Buy rating on the shares. The firm, in its ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Catalyst Pharma (CPRX – Research Report), ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more ...

What Johnson & Johnson and Eli Lilly are saying about Trump’s pharmaceutical tariffs, and Dexcom scores FDA approval for its ...

This study presents an innovative approach to single-atom catalysts, overcoming oxidative addition challenges in cross-coupling reactions for pharmaceuticals.

The fossil fuel industry is pushing Congress for immunity from climate lawsuits that could force the industry to pay billions for misleading the public about the dangers of fossil fuels — attempting ...

Donald Trump’s erratic tariff rollout seems likely to deepen the world’s dependence on China and scare off investment in US ...

Anthropic, the US AI company behind the Claude chatbot, said it would create more than 100 roles in Europe, including in ...

A new light-activated catalyst breaks and resets carbon–halogen bonds to convert racemic mixtures into enantiomerically enriched products. It is the first time that such a technique has targeted bonds ...